- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07693465
Impact of Spinal Alignment on Pelvic Floor Efficiency
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Pelvic floor dysfunction (PFD) may extend beyond the pelvic region by inducing myofascial disturbances in anatomically distant structures connected through the myofascial network. Among these, low back pain (LBP) is one of the most frequently reported musculoskeletal conditions associated with PFD. This relationship is thought to arise from lumbopelvic instability and altered coordination of the core musculature. The pelvic floor muscles (PFMs), together with the transversus abdominis, diaphragm, and multifidus, form an integrated stabilizing system that contributes to spinal stability and postural control. Consequently, dysfunction of the transversus abdominis may compromise not only pelvic floor function but also overall lumbopelvic stability. Women with LBP have been shown to exhibit reduced PFM contraction strength despite preserved transversus abdominis activation, suggesting that impaired PFM function may play a more prominent role in the development of LBP than deficits in the abdominal muscles alone. Conversely, inadequate activation or endurance of the transversus abdominis has also been associated with impaired PFM function. Furthermore, altered movement patterns, dysfunctional breathing, and postural deviations can disrupt load transfer through the lumbopelvic region, thereby increasing the risk of PFD.
There is a dearth of knowledge regarding the effect of spinal alignment on pelvic floor efficiency in nulliparous women. This study, therefore, contributes valuable insights into a relatively unexplored area of nulliparous women's health. By assessing the pelvic floor muscles in nulliparous women with different spinal alignment patterns, including lordosis, kyphosis, and scoliosis, this study may enhance the well-being of nulliparous women, provide a more comprehensive approach to health improvement, help protect them from future pelvic floor dysfunction, and broaden the scope of physiotherapy in women's health.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Giza, Ägypten
- Faculty of Physical Therapy, Cairo University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Nulliparous women.
- Their ages will range from 25 to 35 years old.
- Their body mass index (BMI) will not exceed 29.9 Kg/m2.
Exclusion Criteria:
- Female with congenital spinal deformity.
- Female with a history of neuromuscular disease.
- Female Diagnosed with any systemic disease .
- Female with a history of malignancy and/or ongoing treatment.
- Female with a history of urogenital diseases and surgical history.
- Female with previous spinal surgery.
- Female with previous pregnancy .
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Nulliparous women with thoracolumbar scoliosis
Twenty nulliparous women with thoracolumbar scoliosis.
They will undergo assessment using Formetric analysis and vaginal pressure biofeedback.
|
Kein Eingriff
|
|
Nulliparous women with hyperlordosis
Twenty nulliparous women with hyperlordosis.
They will undergo assessment using Formetric analysis and vaginal pressure biofeedback.
|
Kein Eingriff
|
|
Nulliparous women with thoracic kyphosis
Twenty nulliparous women with thoracic kyphosis.
They will undergo assessment using Formetric analysis and vaginal pressure biofeedback.
|
Kein Eingriff
|
|
Nulliparous women with normal spinal alignment
Twenty nulliparous women with normal spinal alignment.
They will undergo assessment using Formetric analysis and vaginal pressure biofeedback.
|
Kein Eingriff
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pelvic floor muscle strength
Zeitfenster: Baseline
|
Pelvic floor muscle strength was measured using vaginal pressure biofeedback (maximum voluntary contraction pressure).
|
Baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pelvic floor muscle endurance
Zeitfenster: Baseline
|
Pelvic floor muscle endurance was assessed using vaginal pressure biofeedback (duration of sustained maximal voluntary contraction).
|
Baseline
|
|
Spinal alignment angle
Zeitfenster: Baseline
|
It was measured using the DIERS Formetric 4D system.
|
Baseline
|
|
Pelvic floor dysfunction symptoms
Zeitfenster: Baseline
|
Total score and domain scores (bladder, bowel, prolapse, and sexual function) were assessed using the Australian Pelvic Floor Questionnaire (APFQ).
|
Baseline
|
|
Health-related quality of life
Zeitfenster: Baseline
|
It was assessed by using Free online SF-12 Health Survey Version 2 (SF-12v2) score calculator.
The SF-12V2 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health.
|
Baseline
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Afaf Mohamed Mahmoud Botla, PhD, Professor, Cairo University
- Studienleiter: Amira Nagy Abd Ellatief Hamad, PhD, Lecturer, Cairo University
- Studienleiter: Amal Abd Elrahman Mohamed Elborady, Assist. Professor, Cairo University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- P.T.REC/012/005314
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .